Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Chinese Patent Office
US Department of Justice
Deloitte
Julphar
Argus Health
Express Scripts
Moodys
McKinsey

Generated: September 24, 2018

DrugPatentWatch Database Preview

Stavudine - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for stavudine and what is the scope of stavudine freedom to operate?

Stavudine is the generic ingredient in three branded drugs marketed by Bristol Myers Squibb, Aurobindo Pharma, Hetero Labs Ltd Iii, Mylan, Mylan Labs Ltd, and Cipla Ltd, and is included in nine NDAs. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

There are fourteen drug master file entries for stavudine. Nine suppliers are listed for this compound. There are ten tentative approvals for this compound.

Medical Subject Heading (MeSH) Categories for stavudine
Synonyms for stavudine
056S175
1-((2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione
1-((2R,5S)-5-Hydroxymethyl-2,5-dihydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione
1-(2,3-Dideoxy-.beta.-D-glycero-pent-2-enofuranosyl)thymine
1-(2,3-Dideoxy-beta-D-glycero-2-pentenofuranosyl)thymine
1-(2,3-Dideoxy-beta-D-glycero-pent-2-enofuranosyl)thymine
1-(5-Hydroxymethyl-2,5-dihydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione (ddeThd)
1-[(2R,5S)-2,5-Dihydro-5-(hydroxymethyl)-2-furanyl]-5-methyl-2,4(1H,3H)-pyrimidinedione
1-[(2R,5S)-5-(HYDROXYMETHYL)-2,5-DIHYDROFURAN-2-YL]-5-METHYL-1,2,3,4-TETRAHYDROPYRIMIDINE-2,4-DIONE
1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methyl-pyrimidine-2,4-dione
1-[(2R,5S)-5-(Hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4-(1H,3H)-dione
1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4-dione
1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4(1H,3H)-dione
1-[5-(hydroxymethyl)-2,5-dihydro-2-furanyl]-5-methyl-2,4(1H,3H)-pyrimidinedione & Colony-stimulating factor 2
132425-31-1
2'-Thymidinene, 3'-deoxy-
2',3' Didehydro 3' deoxythymidine
2',3'-Anhydrothymidine
2',3'-Anhydrothymidine; d4T
2',3'-Didehydro-2',3'-dideoxythmidine
2',3'-didehydro-2',3'-dideoxythymidine
2',3'-Didehydro-3'-deoxy-thymidine
2',3'-Didehydro-3'-deoxythimidine
2',3'-Didehydro-3'-deoxythymidine
2',3'-DIDEHYDRO-3'-DEOXYTHYMIDINE (DDI)
2',3'-Didehydro-3'-deoxythymidine, >=98% (TLC)
2'',3''-didehydro-3''-deoxythymidine
2'',3''-dideoxy-2'',3''-didehydrothymidine
3'- Azido-3'-deoxythymidine & Granulocyte-macrophage colony-stimulating factor
3'-Deoxy-2'-thymidinene
3'-Deoxy-2',3'-didehydro-D-thymidine
3'-Deoxy-2',3'-didehydrothymidine
3'-deoxythymidin-2'-ene
3''-deoxy-2''-thymidine
3''-deoxy-2'',3''-didehydrothymidine
3056-17-5
A820433
AB0013374
AB00383018_18
AB1009564
ABP000995
AC-5263
AC1L2BQ9
AC1Q6BSH
AJ-12338
AK-77340
AKOS005622554
AN-7246
ANW-26914
BB_NC-1008
BBL033763
BC203877
BDBM50013111
BIDD:GT0082
BMY 27857
BMY-27857
BMY27857
BO9LE4QFZF
BR-77340
Bristol-Myers Brand of Stavudine
Bristol-Myers Squibb Brand of Stavudine
BRN 0618327
C07312
CAS-3056-17-5
CCG-100902
CHEBI:63581
CHEMBL991
cid_18283
cid_5155
CPD000058350
CPD000673569
CS-1872
CTK8B1419
D 1413
D 4T
D 4T (nucleoside)
D00445
D0Z8EX
D3580
d4T
D4T & GM-CSF
D4TMBY-27857-3
DB00649
ddeThd
ddeTyd
Dideoxydidehydrothymidine
DR000449
DSSTox_CID_3819
DSSTox_GSID_23819
DSSTox_RID_77198
DTXSID1023819
Estavudina
Estavudina [INN-Spanish]
EU-0100336
FT-0082665
FT-0603625
H940
HMS2051O20
HMS2234C10
HMS3039O05
HMS3259L21
HMS3261C13
HMS3428C07
HSDB 7338
HY-B0116
J-700246
J10003
KS-00000H34
KS-1115
Lopac0_000336
LP00336
LS-1160
MCULE-9252477726
MFCD00132921
MLS000028546
MLS000759504
MLS001055348
MLS001077292
MLS001424091
MLS006011922
MolPort-002-507-283
NC00152
NC00684
NCGC00023212-03
NCGC00023212-04
NCGC00023212-05
NCGC00023212-07
NCGC00023212-08
NCGC00023212-09
NCGC00023212-10
NCGC00023212-11
NCGC00023212-12
NCGC00023212-13
NCGC00023212-14
NCGC00254372-01
NCGC00258944-01
NCGC00261021-01
NSC 163661
NSC-759897
NSC163661
NSC759897
NU003153
NU007632
Opera_ID_1281
Pharmakon1600-01502339
PubChem5805
Q-201742
RP07238
S-2155
SAM001246729
SAM002589948
sanilvudine
Sanilvudine (JAN)
SC-03292
SCHEMBL38661
SMR000058350
SMR000673569
staduvine
Stavudin
Stavudine (d4T)
Stavudine (USAN/INN)
Stavudine [USAN:BAN:INN]
Stavudine [USAN:INN:BAN]
Stavudine [USAN:USP:INN:BAN]
Stavudine for system suitability, European Pharmacopoeia (EP) Reference Standard
Stavudine, European Pharmacopoeia (EP) Reference Standard
Stavudine, Monosodium Salt
Stavudine, United States Pharmacopeia (USP) Reference Standard
Stavudinum
Stavudinum [INN-Latin]
STK801888
STV
Thymidine, 2',3'-didehydro-, 3'-deoxy-
Thymidine, 2',3'-didehydro-3'-deoxy-
Thymine, 1-(2,3-dideoxy-beta-D-glycero-pent-2-enofuranosyl)- (7CI,8CI)
Thymine, 1-(2,3-dideoxy-beta-D-glycero-pent-2-enofuranosyl)-(7CI,8CI)
Tox21_110886
Tox21_110886_1
Tox21_201393
Tox21_300583
Tox21_500336
UNII-BO9LE4QFZF
XNKLLVCARDGLGL-JGVFFNPUSA-N
Z1695906749
ZB004848
Zent
Zerit
Zerit (TN)
Zerit Xr
Zerit(TM)
Zerut XR
ZINC137884
Tentative approvals for STAVUDINE
Applicant Application No. Strength Dosage Form
➤ Try a Free Trial➤ Try a Free Trial40MG; 150MG; 200MGTABLET; ORAL
➤ Try a Free Trial➤ Try a Free Trial40MG; 150MGTABLET; ORAL
➤ Try a Free Trial➤ Try a Free Trial40MG; 150MG; 200MGTABLET; ORAL

US Patents and Regulatory Information for stavudine

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hetero Labs Ltd Iii STAVUDINE stavudine CAPSULE;ORAL 078957-002 Dec 29, 2008 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Aurobindo Pharma STAVUDINE stavudine CAPSULE;ORAL 077672-002 Dec 29, 2008 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Mylan Labs Ltd STAVUDINE stavudine CAPSULE;ORAL 078775-002 Jan 5, 2009 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Mylan STAVUDINE stavudine CAPSULE;ORAL 079069-002 Dec 29, 2008 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Bristol Myers Squibb ZERIT XR stavudine CAPSULE, EXTENDED RELEASE;ORAL 021453-002 Dec 31, 2002 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Bristol Myers Squibb ZERIT XR stavudine CAPSULE, EXTENDED RELEASE;ORAL 021453-004 Dec 31, 2002 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for stavudine

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bristol Myers Squibb ZERIT XR stavudine CAPSULE, EXTENDED RELEASE;ORAL 021453-001 Dec 31, 2002 ➤ Try a Free Trial ➤ Try a Free Trial
Bristol Myers Squibb ZERIT stavudine CAPSULE;ORAL 020412-004 Jun 24, 1994 ➤ Try a Free Trial ➤ Try a Free Trial
Bristol Myers Squibb ZERIT stavudine CAPSULE;ORAL 020412-005 Jun 24, 1994 ➤ Try a Free Trial ➤ Try a Free Trial
Bristol Myers Squibb ZERIT stavudine CAPSULE;ORAL 020412-003 Jun 24, 1994 ➤ Try a Free Trial ➤ Try a Free Trial
Bristol Myers Squibb ZERIT XR stavudine CAPSULE, EXTENDED RELEASE;ORAL 021453-004 Dec 31, 2002 ➤ Try a Free Trial ➤ Try a Free Trial
Bristol Myers Squibb ZERIT XR stavudine CAPSULE, EXTENDED RELEASE;ORAL 021453-003 Dec 31, 2002 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for stavudine

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB96/049 United Kingdom ➤ Try a Free Trial PRODUCT NAME: STAVUDINE; REGISTERED: UK EU/1/96/009/001 19960508; UK EU/1/96/009/002 19960508; UK EU/1/96/009/003 19960508; UK EU/1/96/009/004 19960508; UK EU/1/96/009/005 19960508; UK EU/1/96/009/006 19960508; UK EU/1/96/009/007 19960508; UK EU/1/96/009/008 19960508; UK EU/1/96/009/009 19960508
C0039 Belgium ➤ Try a Free Trial PRODUCT NAME: STAVUDINE; REGISTRATION NO/DATE: EU/1/96/009/001 19960508
60024 Netherlands ➤ Try a Free Trial PRODUCT NAME: STAVUDINE; REGISTRATION NO/DATE: EU/1/96/009/001 - EU/1/96/009/009 19960508
C0040 Belgium ➤ Try a Free Trial PRODUCT NAME: STAVUDINE; NAT. REGISTRATION NO/DATE: EU/1/96/009/001-009 19960509; FIRST REGISTRATION:
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Chinese Patent Office
US Department of Justice
Deloitte
Julphar
Argus Health
Express Scripts
Moodys
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.